VOC is Expanding: From Breath Diagnostics to New Frontiers in Early Detection and Prevention

We are building on a strong commercial foundation in breath diagnostics with high-quality products, excellent user feedback on quality, usability and service, and a competitive moat built on innovative products, quality, IVDR compliance and regulatory excellence.

At the same time, we are expanding our scientific pipeline and opening new fields for growth:

• Together with Klinikum Kulmbach and the University of Bayreuth, and supported by Siemens Healthineers, we have launched new research exploring the association between fatty liver disease and SIBO.
• Our own SIBO plus study is advancing research into hydrogen sulfide SIBO and the development of new diagnostic approaches.
• We are preparing a colorectal cancer risk study with the long-term goal of contributing to improved colorectal cancer screening and prevention.
• We are expanding our breath test portfolio into metabolic disease by integrating additional biomarkers creating opportunities for earlier detection and prevention while opening a new business field for VOC.

For VOC, these developments bring together three important growth drivers:

Commercial growth in B2C and B2B - Clinical research and strategic partnerships -
A growing pipeline of innovative breath-based diagnostics.

Our ambition is to expand breath diagnostics beyond today’s applications and create new value for patients, healthcare partners and shareholders.

We are looking forward to the next chapter of VOC.